PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Treating sleeping sickness

PSI-SGKB [doi:10.1038/fa_psisgkb.2010.16]
Featured Article - May 2010
Short description: A potential new drug kills the bloodstream parasite that causes this disease.

X-ray crystal structure of DDD85646 bound to LmN-myristoyltransferase.

African sleeping sickness, also known as human African trypanosomiasis, kills 30,000 people each year, and there is currently no effective and safe treatment. Frearson et al. from the University of Dundee, in collaboration with the University of York and the Structural Genomics Consortium in Toronto, report a new potential drug that kills the bloodstream parasite that causes this disease.

N-myristoylation is an important eukaryotic modification required for many biological processes. In the parasite that causes sleeping sickness, Trypanosoma brucei, this reaction is catalysed by N-myristoyltransferase, which has at least 60 substrates and is probably involved in many downstream processes. The central role of this enzyme suggested that its inhibition might be an effective way to treat the disease.

This isn't the first time N-myristoyltransferase has attracted attention though. It has been investigated as a potential anticancer, antiviral and antifungal target, too, and looks promising as a drug target because it is possible to distinguish between the human and the parasitic form. Unfortunately, no useful and safe inhibitors have been identified until now.

But anti-fungal N-myristoyltransferase programs were discontinued because of an inability to identify broad spectrum inhibitors. And as for cancer treatment, no one has yet identified potent human N-myristoyltransferase inhibitors with which to fully validate this enzyme.

Frearson et al. screened 62,000 compounds for a potential lead and eventually identified one, DDD85646, that inhibits N-myristoyltransferase and prevents growth of T. brucei. Testing of this potential drug in a mouse model of human African trypanosomiasis proved successful, with all mice cured of this disease when the compound was taken orally. Even mice with a clinically relevant form T. brucei rhodesiense were cured.

These promising results against T. brucei in the bloodstream make DDD85646 an exciting prospect for drug development, but an effective treatment needs to also work at a later stage of infection, when T. brucei has crossed into the central nervous system. Ideally, its selectivity for the T. brucei N-myristoyltransferase rather than the human form should be improved too. To enhance DD85646, it's important to understand how it works, and that's where the Structural Genomics Consortium helped out.

Inhibition assays had indicated that DDD85646 competes with the peptide substrate, but in the absence of a three-dimensional structure of N-myristoyltransferase the exact mechanism was not known. T. brucei N-myristoyltransferase would not crystallize but the highly similar Leishmania major form, which has 74% sequence identity with TbNMT and 94% identity within the peptide binding site, did.

The structure revealed that DDD85646 does indeed bind in the peptide substrate pocket of N-myristoyltransferase, but the structure showed something very interesting: the interactions between the compound and enzyme are mostly through water-mediated interactions rather than normal hydrogen bonding. Computer modeling of this complex is highly unlikely to have been able to predict this, illustrating the importance of obtaining the actual structure.

Related articles

The cancer kinome

Safer Alzheimer's drugs

Two component signaling

Maria Hodges


  1. J. A. Frearson et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness.
    Nature 464, 728-732 (2010). doi:10.1038/nature08893

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health